Spyre Therapeutics
SYRE
66 hedge funds and large institutions have $25.4M invested in Spyre Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 28 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
0.07% less ownership
Funds ownership: 3.36% → 3.28% (-0.07%)
20% less funds holding
Funds holding: 83 → 66 (-17)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 28
73% less capital invested
Capital invested by funds: $95.4M → $25.4M (-$70M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$5.32M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$3.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.5M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$3.28M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$3.62M |
| 2 |
BlackRock
New York
|
-$2.6M |
| 3 |
O
OrbiMed
New York
|
-$1.62M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.19M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1M |
SYRE Hedge Fund Activity: Q2 2022 in Review
66 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2022, worth a combined $25.4M — down 73% from $95.4M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of SYRE and 13 opened new positions — a net loss of 15 holders — while 17 trimmed existing stakes and 21 added.
The largest buyer was Sio Capital Management, adding an estimated $5.32M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $3.62M sold.
- 66 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2022, down from 83 in Q1 2022.
- Funds reported $25.4M of Spyre Therapeutics stock for Q2 2022, down 73% quarter-over-quarter.
- 13 funds opened new Spyre Therapeutics positions in Q2 2022 and 28 closed out, a net change of -15 holders.
- The largest Spyre Therapeutics buyer in Q2 2022 was Sio Capital Management, an estimated $5.32M added.
- The largest Spyre Therapeutics seller in Q2 2022 was Laurion Capital Management, an estimated $3.62M sold.
Based on aggregated 13F filings for Q2 2022.